Physician profile
Brian P Murphy
NPI 1699796375
$3,546.61
in general payments reported to CMS, 2019-2025
21 companies · $1,335 in 2025
The $1,335 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.29 · 2020: $145 · 2021: $386 · 2022: $345 · 2023: $516 · 2024: $792 · 2025: $1,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.65 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.33 | 2021-2025 | |
| Lundbeck LLC | $348.35 | 2024-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $304.70 | 2023-2024 | Ajovy, Austedo Xr |
| Argenx US, INC. | $217.15 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $195.75 | 2022-2024 | Xadago, Apokyn, Apokyn |
| Biohaven Pharmaceuticals, INC. | $191.39 | 2021 | |
| Lilly USA, LLC | $168.38 | 2024-2025 | Amyvid, Kisunla, Taltz |
| Allergan, INC. | $133.82 | 2020 | |
| Pfizer INC. | $97.87 | 2023-2025 | |
| Axsome Therapeutics, INC. | $96.95 | 2025 | Symbravo |
| Novartis Pharmaceuticals Corporation | $69.41 | 2025 | |
| Janssen Biotech, INC. | $50.92 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.66 | 2025 | Hyqvia |
| Tris Pharma INC | $28.57 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.37 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $26.58 | 2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $26.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Acadia Pharmaceuticals INC | $17.41 | 2025 | Nuplazid |
| Amgen INC. | $12.55 | 2022 | |
| Csl Behring | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.